Jaguar Health announced that Jaguar family companies Napo Pharmaceuticals and Napo Therapeutics have submitted a Clinical Trial Application to the Italian and German health authorities to initiate a phase 2 clinical trial of Jaguar’s novel plant-based prescription drug crofelemer for treatment of short bowel syndrome, or SBS, with intestinal failure in adults. Napo Therapeutics has also submitted a CTA to AIFA, the Italian health authority, for the conduct of a clinical trial in pediatric patients with microvillus inclusion disease, or MVID, and the approval request process is also underway for this trial in the United Arab Emirates with Dubai Health. The MVID clinical trial is being conducted under an active U.S. Investigational New Drug in the U.S., the company noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health establishes INAD file with FDA’s CVM for crofelemer
- Jaguar Health files $75M mixed securities shelf
- Biotech Alert: Searches spiking for these stocks today
- Jaguar Health appoints Catherine Miller Collis as SVP, growth strategy
- Jaguar Health enters in-license agreement with Venture Life Group for Gelclair